

REFERENCES – TOWN HALL 92 – 11-19-2023

A FASCINATING PAPER IN *NATURE* DEMONSTRATED THAT HISTORICAL NARRATIVES ABOUT THE COVID-19 PANDEMIC ARE MOTIVATIONALLY BIASED.

<https://www.nature.com/articles/d41586-023-03082-7>

A NATURE COMMUNICATIONS PAPER FOUND THAT AEROSOLIZED SARS-CoV-2 HUMAN MONOCLONAL ANTIBODIES LIMITED VIRAL REPLICATION AND LUNG PATHOLOGY IN MACAQUES.

<https://www.nature.com/articles/s41467-023-42440-x>

A LETTER TO THE EDITOR OF THE *NEW ENGLAND JOURNAL OF MEDICINE* DESCRIBES AN ASSOCIATION OF SARS-CoV-2 INFECTION DURING EARLY WEEKS OF GESTATION AND SITUUS INVERSUS IN NEWBORNS IN CHINA.

https://www.nejm.org/doi/full/10.1056/NEJMc2309215?query=featured_coronavirus

AN ARTICLE IN THE *NEW ENGLAND JOURNAL OF MEDICINE* DESCRIBED THE EFFICACY OF CONVALESCENT PLASMA FOR COVID-19-INDUCED ARDS IN MECHANICALLY VENTILATED PATIENTS.

<https://www.nejm.org/doi/10.1056/NEJMoa2209502>

AN ARTICLE IN THE *BRITISH MEDICAL JOURNAL* DISCUSSES WHAT WE KNOW ABOUT COVID IN IMMUNOCOMPROMISED PEOPLE.

<https://www.bmj.com/content/383/bmj.p1612>

A *JAMA* STUDY DESCRIBES THE RESULTS OF TWO RANDOMIZED CLINICAL TRIALS DEMONSTRATING LOW PROBABILITY OF IMPROVING PRIMARY COMPOSITE OUTCOMES AND SURVIVAL BY THE INTRAVENOUS ADMINISTRATION OF VITAMIN C IN PATIENTS WITH COVID.

<https://jamanetwork.com/journals/jama/fullarticle/2811212>

A *JAMA INTERNAL MEDICINE* PAPER ARGUES FOR THE USE OF ARTIFICIAL INTELLIGENCE IN MAINTAINING VIGILANCE FOR HEALTH DISINFORMATION

<https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2811333>

A *JAMA NETWORK OPEN* STUDY FOUND THAT MATERNAL mRNA VACCINATION WAS ASSOCIATED WITH A LOWER RISK OF OMICRON SARS-CoV-2 INFECTION AMONG INFANTS UP TO 6 MONTHS OF AGE ONLY IF THE VACCINE WAS GIVEN DURING THE ANTENATAL PERIOD.

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2811644>

ANOTHER *JAMA NETWORK OPEN* CROSS-SECTIONAL STUDY OF RESPIRATORY INFECTIONS IN CHILDREN WITH AND WITHOUT MEDICAL COMPLEXITY FOUND A SUBSTANTIAL DECREASE IN SEVERE RESPIRATORY DISEASE DURING THE FIRST 2 YEARS OF THE PANDEMIC COMPARED WITH THE 3 PREPANDEMIC YEARS.

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2811817>

ANOTHER *JAMA NETWORK OPEN* STUDY ASSESSED NOSOCOMIAL SARS-CoV-2 INFECTIONS AND MORTALITY DURING UNIQUE COVID-19 EPIDEMIC WAVES.

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2811653>

AN EDITORIAL IN *JAMA NETWORK OPEN* ACCOMPANYING THE PRIOR STUDY ARGUES FOR THE CONTINUED STRATEGIC USE OF INTERVENTIONS IN HEALTHCARE SETTINGS TO DECREASE RISKS FOR RESPIRATORY VIRUS SPREAD.

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2811647>

A PAPER IN *JAMA* FROM THE NIH ACTIV PROGRAM DEMONSTRATED LACK OF EFFICACY OF FLUVOXAMINE IN HASTENING TIME TO RECOVERY IN OUTPATIENTS WITH COVID.

<https://jamanetwork.com/journals/jama/fullarticle/2812204>

REFERENCES – TOWN HALL 92 – 11-16-2023 (CONTINUED)

A *JAMA* EDITORIAL ACCOMPANYING THE FLUVOXAMINE STUDY APPLAUDS THE ACTIV PLATFORM AS A TEMPLATE FOR LARGE CLINICAL TRIALS.

<https://jamanetwork.com/journals/jama/fullarticle/2812205>

A *JAMA* OPINION PIECE IDENTIFIES PHYSICIANS' REFUSAL TO WEAR MASKS FOR IMMUNOCOMPROMISED PATIENTS AS AN ETHICAL DILEMMA.

<https://jamanetwork.com/journals/jama-health-forum/fullarticle/2811897>

A PREPRINT POSTED ON BIORxIV LAST MONTH SUGGESTS THAT CONCURRENT ADMINISTRATION OF COVID-19 AND INFLUENZA VACCINES ENHANCES SPIKE-SPECIFIC ANTIBODY RESPONSES.

<https://www.biorxiv.org/content/10.1101/2023.09.12.557347v>

THE CENTERS FOR DISEASE CONTROL AND PREVENTION REPORTED THAT APPROXIMATELY 36 MILLION ADULT AMERICANS HAVE RECEIVED THE UPDATED COVID-19 VACCINE.

<https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-adults.html>

PFIZER-BIONTECH ANNOUNCED POSITIVE RESULTS OF PHASE I AND II STUDIES OF THEIR NEW COMBINATION INFLUENZA AND COVID VACCINE AND ALSO ANNOUNCED THE INITIATION OF A PHASE III STUDY OF THIS NEW VACCINE.

<https://investors.pfizer.com/Investors/News/news-details/2023/Pfizer-and-BioNTech-Announce-Positive-Topline-Data-for-mRNA-based-Combination-Vaccine-Program-Against-Influenza-and-COVID-19/default.aspx>